Page last updated: 2024-10-24

chlordiazepoxide and Alcohol Drinking

chlordiazepoxide has been researched along with Alcohol Drinking in 26 studies

Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.

Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.

Research Excerpts

ExcerptRelevanceReference
"Lorazepam was used as rescue medication."2.82A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. ( Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016)
"Buspirone was without important effects on the high alcohol preferring rats."1.29Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993)
"Three mothers of infants with holoprosencephaly consumed alcohol heavily in pregnancy."1.28Holoprosencephaly as a possible embryonic alcohol effect. ( Andrews, WL; Ronen, GM, 1991)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-199017 (65.38)18.7374
1990's7 (26.92)18.2507
2000's0 (0.00)29.6817
2010's2 (7.69)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Manzo, L1
Donaire, R1
Sabariego, M1
Papini, MR1
Torres, C1
Girish, K1
Vikram Reddy, K1
Pandit, LV1
Pundarikaksha, HP1
Vijendra, R1
Vasundara, K1
Manjunatha, R1
Nagraj, M1
Shruthi, R1
WOLF, S1
FOXWELL, NH1
KURLAND, AA1
Roehrs, T1
Yang, O1
Samson, H1
Chan, AW2
Schanley, DL2
Leong, FW2
Brot, MD1
Koob, GF2
Britton, KT1
Criswell, HE1
Overstreet, DH1
Rezvani, AH1
Johnson, KB1
Simson, PE1
Knapp, DJ1
Moy, SS1
Breese, GR1
Rassnick, S1
D'Amico, E1
Riley, E1
Monti, PM1
Rohsenow, DJ1
Rubonis, AV1
Niaura, RS1
Sirota, AD1
Colby, SM1
Abrams, DB1
Meert, TF1
Söderpalm, AH1
Hansen, S1
Ritson, EB1
Palva, ES1
Linnoila, M1
Harris, RA1
Case, J1
Barrett, JE1
Weinberg, ES1
Underwood Ground, KE1
Ronen, GM1
Andrews, WL1
Gauvin, DV1
Harland, RD1
Criado, JR1
Michaelis, RC1
Holloway, FA1
Forney, RB1
Mello, NK1
Mendelson, JH1
Rosenberg, CM1
Waller, JA1
Belfer, ML1
Shader, RI1
Carroll, M1
Harmatz, JS1
Milner, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652]133 participants (Actual)Interventional2011-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Opioid Withdrawal)

The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-0.44

Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Opioid Withdrawal)

The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-2.68

Change in Roland-Morris Disability Index (RMDI) From Baseline (Prevention of Opioid Withdrawal)

The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Prevention of Opioid Withdrawal-2.59

Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Physical Dependence)

The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in BDIS (Ondansetron)Change in BDIS (Placebo)
Prevention of Physical Dependence-0.60.2

Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal)

"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in OOWS (Ondansetron)Change in OOWS (Placebo)
Prevention of Opioid Withdrawal3.63.6

Change in Objective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence)

"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in OOWS (Ondansetron)Change in OOWS (Placebo)
Prevention of Physical Dependence4.54.2

Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Physical Dependence)

The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in VAS Score (Ondansetron)Change in VAS Score (Placebo)
Prevention of Physical Dependence-2.9-2.8

Change in Roland-Morris Disability (RMDI) Index From Baseline (Prevention of Physical Dependence)

The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)

Interventionunits on a scale (Mean)
Change in RMDI (Ondansetron)Change in RMDI (Placebo)
Prevention of Physical Dependence-4.6-2.0

Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal)

The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in SOWS (Ondansetron)Change in SOWS (Placebo)
Prevention of Opioid Withdrawal12.512.2

Change in Subjective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence)

The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in SOWS (Ondansetron)Change in SOWS (Placebo)
Prevention of Physical Dependence16.412.0

Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal)

Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in POMS Score (Ondansetron)Change in POMS Score (Placebo)
Prevention of Opioid Withdrawal29.328.3

Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Physical Dependence)

(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose

Interventionunits on a scale (Mean)
Change in POMS (Ondansetron)Change in POMS (Placebo)
Prevention of Physical Dependence36.129.2

Reviews

1 review available for chlordiazepoxide and Alcohol Drinking

ArticleYear
Anxiolytic effects of steroid hormones during the estrous cycle. Interactions with ethanol.
    Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism, 1995, Volume: 12

    Topics: Alcohol Drinking; Anesthetics; Animals; Anxiety; Appetitive Behavior; Arousal; Brain; Chlordiazepoxi

1995

Trials

4 trials available for chlordiazepoxide and Alcohol Drinking

ArticleYear
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
    Biomedical journal, 2016, Volume: 39, Issue:1

    Topics: Adult; Alcohol Drinking; Baclofen; Chlordiazepoxide; Diazepam; Humans; Lorazepam; Male; Middle Aged;

2016
Effect of active metabolites of chlordiazepoxide and diazepam, alone or in combination with alcohol, on psychomotor skills related to driving.
    European journal of clinical pharmacology, 1978, Jul-30, Volume: 13, Issue:5

    Topics: Adult; Alcohol Drinking; Automobile Driving; Chlordiazepoxide; Clinical Trials as Topic; Diazepam; D

1978
International seminar research on alcohol, drugs and driving.
    Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1973, Volume: 6, Issue:2

    Topics: Alcohol Drinking; Auditory Perception; Automobile Driving; Caffeine; Chlordiazepoxide; Clinical Tria

1973
Drug maintenance in the outpatient treatment of chronic alcoholism.
    Archives of general psychiatry, 1974, Volume: 30, Issue:3

    Topics: Adult; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Automobile Driving; Boston; Chlordiazep

1974

Other Studies

21 other studies available for chlordiazepoxide and Alcohol Drinking

ArticleYear
Anti-anxiety self-medication in rats: oral consumption of chlordiazepoxide and ethanol after reward devaluation.
    Behavioural brain research, 2015, Feb-01, Volume: 278

    Topics: Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Conditioning, Operant; Di

2015
INCIDENCE OF DRINKING AMONG HOSPITALIZED CONVALESCING ALCOHOLICS.
    Quarterly journal of studies on alcohol, 1965, Volume: 26

    Topics: Alcohol Drinking; Alcoholics; Alcoholism; Chlordiazepoxide; Convalescence; Hospitalization; Humans;

1965
Chlordiazepoxide's interaction with ethanol intake in the rat: relation to ethanol exposure paradigms.
    Pharmacology, biochemistry, and behavior, 1984, Volume: 20, Issue:6

    Topics: Alcohol Drinking; Animals; Body Weight; Chlordiazepoxide; Diet; Drug Interactions; Environment; Etha

1984
Long-lasting reduction in ethanol selection after involuntary intake of ethanol/chlordiazepoxide.
    Pharmacology, biochemistry, and behavior, 1983, Volume: 19, Issue:2

    Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Drinking Behavior; Ethanol; Food Preferences; Male; Mic

1983
Influence of chlordiazepoxide on alcohol consumption in mice.
    Pharmacology, biochemistry, and behavior, 1983, Volume: 18, Issue:5

    Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Male; Mice; Mice, Inbred C57BL; Taste; Time Factors

1983
Effects of ethanol, MK-801, and chlordiazepoxide on locomotor activity in different rat lines: dissociation of locomotor stimulation from ethanol preference.
    Alcoholism, clinical and experimental research, 1994, Volume: 18, Issue:4

    Topics: Alcohol Drinking; Animals; Arousal; Chlordiazepoxide; Dizocilpine Maleate; Dose-Response Relationshi

1994
GABA antagonist and benzodiazepine partial inverse agonist reduce motivated responding for ethanol.
    Alcoholism, clinical and experimental research, 1993, Volume: 17, Issue:1

    Topics: Alcohol Drinking; Animals; Appetitive Behavior; Arousal; Azides; Benzodiazepines; Brain; Chlordiazep

1993
Alcohol cue reactivity: effects of detoxification and extended exposure.
    Journal of studies on alcohol, 1993, Volume: 54, Issue:2

    Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Arousal

1993
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
    Alcohol and alcoholism (Oxford, Oxfordshire), 1993, Volume: 28, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati

1993
Benzodiazepines enhance the consumption and palatability of alcohol in the rat.
    Psychopharmacology, 1998, Volume: 137, Issue:3

    Topics: Alcohol Drinking; Animals; Anti-Anxiety Agents; Brain; Chlordiazepoxide; Diazepam; Dose-Response Rel

1998
Psychological medicine. Treatment of alcoholism.
    British medical journal, 1975, Apr-19, Volume: 2, Issue:5963

    Topics: Adolescent; Adult; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholics Anonymous; Alcoholism;

1975
Effects of maternal consumption of ethanol, barbital, or chlordiazepoxide on the behavior of the offspring.
    Behavioral and neural biology, 1979, Volume: 26, Issue:2

    Topics: Alcohol Drinking; Animals; Animals, Newborn; Avoidance Learning; Barbital; Barbiturates; Behavior, A

1979
Effects of chlordiazepoxide on schedule-induced water and alcohol consumption in the squirrel monkey.
    Psychopharmacologia, 1975, Volume: 40, Issue:4

    Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Drinking Behavior; Haplorhini; Male; Reinforcement Sche

1975
Impaired pilot performance: drugs or alcohol.
    Aviation, space, and environmental medicine, 1975, Volume: 46, Issue:10

    Topics: Accidents, Aviation; Aerospace Medicine; Alcohol Drinking; Chlordiazepoxide; Ethanol; Humans

1975
Holoprosencephaly as a possible embryonic alcohol effect.
    American journal of medical genetics, 1991, Aug-01, Volume: 40, Issue:2

    Topics: Abnormalities, Drug-Induced; Alcohol Drinking; Chlordiazepoxide; Female; Holoprosencephaly; Humans;

1991
The discriminative stimulus properties of ethanol and acute ethanol withdrawal states in rats.
    Drug and alcohol dependence, 1989, Volume: 24, Issue:2

    Topics: Affect; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholic Intoxication; Animals; Arousal; Chl

1989
Behavioral studies of sleep patterns in alcoholics during intoxication and withdrawal.
    The Journal of pharmacology and experimental therapeutics, 1970, Volume: 175, Issue:1

    Topics: Adult; Alcohol Drinking; Alcoholism; Chlordiazepoxide; Ethanol; Hallucinations; Humans; Hypnotics an

1970
Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age.
    The New England journal of medicine, 1973, 02-08, Volume: 288, Issue:6

    Topics: Adult; Age Factors; Aged; Alcohol Drinking; Anxiety; Brain; Chlordiazepoxide; Depression, Chemical;

1973
Drugs and highway crashes. Can we separate fact from fancy?
    JAMA, 1971, Mar-01, Volume: 215, Issue:9

    Topics: Accidents, Traffic; Age Factors; Alcohol Drinking; Automobile Driving; Cannabis; Chlordiazepoxide; C

1971
Alcoholism in women.
    Archives of general psychiatry, 1971, Volume: 25, Issue:6

    Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Chlordiazepoxide; Depression; Diazepam; Female;

1971
Drinking and driving in 753 general practice and psychiatric patients on psychotropic drugs.
    The British journal of psychiatry : the journal of mental science, 1969, Volume: 115, Issue:518

    Topics: Alcohol Drinking; Amitriptyline; Automobile Driving; Barbiturates; Chlordiazepoxide; Diazepam; Drug

1969